TelyRx Holdings Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	42.92	9.53	0.03
Revenue Growth (YoY)	350.27%	35207.41%	-
Cost of Revenue	19.61	6.02	0.03
Gross Profit	23.32	3.51	0
Selling, General & Admin	27.3	7.16	0.72
Operating Expenses	28.08	7.44	0.75
Operating Income	-4.76	-3.93	-0.75
Interest Expense	-0.66	-0.93	-0.89
Other Non Operating Income (Expenses)	0.02	-	-
EBT Excluding Unusual Items	-5.41	-4.86	-1.64
Other Unusual Items	-	0.03	-
Pretax Income	-5.41	-4.83	-1.64
Income Tax Expense	0.02	-	-
Earnings From Continuing Operations	-5.43	-4.83	-1.64
Earnings From Discontinued Operations	-	-8.65	-2.76
Net Income	-5.43	-13.48	-4.39
Net Income to Common	-5.43	-13.48	-4.39
Shares Outstanding (Basic)	11	8	-
Shares Outstanding (Diluted)	11	8	-
Shares Change (YoY)	40.47%	-	-
EPS (Basic)	-0.51	-1.77	-
EPS (Diluted)	-0.51	-1.77	-
Free Cash Flow	-1.36	-3.07	-2.51
Free Cash Flow Per Share	-0.13	-0.40	-
Gross Margin	54.32%	36.84%	7.41%
Operating Margin	-11.10%	-41.19%	-2762.96%
Profit Margin	-12.64%	-141.44%	-16274.07%
Free Cash Flow Margin	-3.16%	-32.17%	-9277.78%
EBITDA	-4.67	-3.92	-0.71
EBITDA Margin	-10.87%	-41.10%	-
D&A For EBITDA	0.1	0.01	0.03
EBIT	-4.76	-3.93	-0.75
EBIT Margin	-11.10%	-41.19%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.